Artificial intelligence could help us to assess scans of patients with bone disease, thanks to an innovative software toolkit developed at the BRC.

Experts at The Royal Marsden and The Institute of Cancer Research, with support from the NIHR BRC at The Royal Marsden and ICR, are leading on pioneering cancer research, with their work being published in high-profile journals.

Researchers at The Royal Marsden NHS Foundation Trust, the Francis Crick Institute and University College London have found immune cell patterns in tumours that can help predict whether patients with kidney cancer will respond to immunotherapy. 

A local breast cancer prevention project is aiming to inform and empower women to make lifestyle changes to reduce their risk of developing the disease. 

Artificial Intelligence has helped researchers make major progress in treating an incurable childhood brain cancer. 

Pioneered at The Royal Marsden NHS Foundation Trust, with support from the NIHR BRC at The Royal Marsden and ICR, liquid biopsies allow clinicians at The Royal Marsden to personalise treatments for a range of cancers and spot recurring disease sooner using a simple blood test. 

Dr Hardeep Singh Kalsi is a Clinical Research Fellow, whose role is funded by The Royal Marsden Cancer Charity, and member of the NIHR BRC’s Early Diagnosis & Detection team.

As Head of Clinical Genomics (Research) at The Royal Marsden, Professor Michael Hubank leads the Clinical Genomics Translational Research Team in the Centre for Molecular Pathology – a state-of-the-art facility that is funded through the NIHR BRC.

By using sophisticated computing tools and artificial intelligence to uncover crucial clues about tumours, the new Integrated Pathology Unit at The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, is set to bring the discipline into the 21st century.

Research funded by the NIHR Biomedical Research Centre (BRC) at The Royal Marsden and The Institute of Cancer Research, London (ICR) and pharmaceutical company Kortuc is investigating whether the common antiseptic hydrogen peroxide can enhance the cancer-killing effects of radiotherapy in breast cancer patients.